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Abstract
CCAAT/enhancer binding protein c (C/EBPc) is a member of the C/EBP family of transcription factors, which lacks known
activation domains. C/EBPc was originally described as an inhibitor of C/EBP transactivation potential. However, previous
study demonstrates that C/EBPc augments the C/EBPb stimulatory activity in lipopolysaccharide induction of IL-6 promoter
in a B lymphoblast cell line. These data indicate a complexing functional role for C/EBPc in regulating gene expression.
Furthermore, the expression and function of C/EBPc during inflammation are still largely unknown. In this study, we
demonstrate that C/EBPc activation was induced by IL-1b treatment in lung epithelial cells. Importantly, we demonstrate for
the first time that C/EBPc plays a critical role in regulating IL-1b-induced IL-6 expression in both mouse primary alveolar type
II epithelial cells and a lung epithelial cell line, MLE12. We further provide the evidence that C/EBPc inhibits IL-6 expression
by inhibiting C/EBPb but not NF-kB stimulatory activity in MLE12 cells. These findings suggest that C/EBPc is a key
transcription factor that regulates the IL-6 expression in alveolar epithelial cells, and may play an important regulatory role
in lung inflammatory responses.
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Introduction
As one of the major cell types comprising alveolar epithelial
tissue, the alveolar type II epithelial cells play an important role in
maintaining alveolar integrity by forming the key alveolar barrier,
repairing damaged type I cells, and being the source of alveolar
surfactant [1,2,3]. Increasing studies also suggest a critical role for
alveolar type II epithelial cells in regulating local lung inflamma-
tory response. For example, our previous study and others have
suggested that alveolar type II epithelial cells may play special roles
in counteracting microbes by releasing cytokines and chemokines
that recruit both dendritic cells and alveolar macrophages to the
site of infection [4,5,6,7]. However, the potential role of alveolar
type II epithelial cells in lung innate immunity and the molecular
mechanisms whereby the expressions of inflammatory mediators
are regulated in alveolar type II epithelial cells remain largely
unknown. IL-1b is one of the most biologically active cytokines in
edema fluid and bronchoalveolar lavage (BAL) fluid from patients
at an early stage of acute respiratory distress syndrome (ARDS).
Moreover, IL-1b has been shown to affect the function of the lung
epithelial barrier. IL-1b is known to modulate the activity of many
transcription factors including NF-kB and C/EBPs. However, the
role of C/EBPs in IL-1b-mediated inflammatory responses in
alveolar type II epithelial cells remains unknown. The goal of the
current study was to investigate the role of C/EBPc in IL-1b-
stimulated IL-6 production from alveolar type II epithelial cells.
C/EBPa,- b,- d,- e,- c, and -f comprise a family of basic region-
leucine zipper (bZIP) transcription factors that dimerize through a
leucine zipper and bind to DNA through an adjacent basic region.
All C/EBP members can form homo- and hetero-dimers with
other family members. C/EBPs can activate transcription from
promoters that contain a consensus binding site: 59-T(T/
G)NNGNAA(T/G)-39 [8]. Among them, C/EBPb and -d appear
to be effectors in the induction of genes responsive to LPS, IL-1b
or IL-6 stimulation, and have been implicated in the regulation of
inflammatory mediators as well as other gene products associated
with the activation of macrophages and the acute phase
inflammatory response [9] [10,11]. C/EBPc is a ubiquitously
expressed member of the C/EBP family of transcription factors
that has been shown to be an inhibitor of C/EBP transcriptional
activators. Different from C/EBPb and -d, C/EBPc was proposed
to act as a buffer against C/EBP-mediated activation because of
the fact that C/EBPc lacks known activation domains [12]. C/
EBPc-deficient mice showed a high mortality rate within 48 h
after birth [13]. Although C/EBPc chimeras showed normal T
and B cell development, the cytolytic functions of their splenic
natural killer cells after stimulation with cytokines such as IL-12,
IL-18 and IL-2 were significantly reduced [13]. However, the role
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35492of C/EBPc in inflammation remains largely unknown. In the
current study, we demonstrate that C/EBPc expression is induced
by IL-1b in lung epithelial cells, and apparently contributes to the
inhibition of IL-1b-mediated IL-6 production. Furthermore, we
show that C/EBPc inhibits IL-6 expression by inhibiting C/EBPb
stimulatory activity. In sharp contrast, NF-kB activity is not
impaired by C/EBPc. The data suggest that C/EBPc may play an
important regulatory role in lung inflammatory responses.
Results
C/EBPc suppresses IL-1b-induced IL-6 production in
MLE12 cells
Little is known about the expression and function of C/EBPc
during inflammation. We evaluated the time course of C/EBP
activation in lung epithelial cells by EMSA, using nuclear extracts
from MLE12, a lung epithelial cell line, obtained at various time
points after IL-1b treatment. As shown in Fig. 1A, at time 0, low
levels of constitutive C/EBPs (mainly C/EBPb and C/EBPc) were
observed. C/EBP activation became stronger by 3 h, then
decreased to control levels (Fig. 1A). To determine if increased
oligonucleotide binding to C/EBPc was caused by increased
transcriptional expression of C/EBPc, we conducted Real Time
PCR experiments. As shown in Fig. 1B, constitutive levels of C/
EBPc mRNA expression in MLE12 cells were observed at 0, 3,
and 6 h after IL-1b treatment, with modest decreases at 12 and
24 h. These data suggest that the C/EBPc DNA binding was
mainly regulated at post-transcriptional level. C/EBPb has been
shown to participate in IL-1b signaling such as mediating IL-6
production [14]. However, the role of C/EBPc in IL-1b signaling
is unclear. We therefore determined whether C/EBPc expression
in MLE12 cells has any effect on IL-1b-induced IL-6 production.
MLE 12 cells were transfected with control siRNA or C/EBPc
siRNA before IL-1b challenge. We demonstrated that C/EBPc
siRNA could effectively suppress the endogenous C/EBPc
expression in MLE12 cells (Fig. 1C). We found that knockdown
of C/EBPc significantly increased IL-1b-stimulated IL-6 expres-
sion at mRNA level (Fig. 1D). Moreover, we show that IL-6
production at protein level was increasingly elevated in a time-
dependent manner when the MLE12 cells were stimulated with
IL-1b (Fig. 1E). Importantly, knockdown of C/EBPc in MLE12
cells led to a significant increase of IL-1b-stimulated IL-6 secretion
(more than 300% increase) at all time points when compared with
control group (Fig. 1E), suggesting a negative regulatory role of C/
EBPc in IL-1b-induced IL-6 expression.
To further determine the C/EBPc regulation of IL-6 expres-
sion, we infected MLE12 cells with adenovirus that could induce
C/EBPc expression (Adeno-C/EBPc). As shown in Fig. 2A, cells
infected with Adeno-C/EBPc exhibited high level of C/EBPc
protein expression. We further demonstrated that the exogenously
expressed C/EBPc can bind to C/EBP binding site in the IL-6
promoter by EMSA (Fig. 2B). We next showed that C/EBPc
expression significantly suppressed IL-1b-induced IL-6 expression
at both mRNA and protein levels (Fig. 2C and D). To further
determine the ability of C/EBPc to suppress IL-1b-induced IL-6
expression, MLE12 cells were transfected with an IL-6 promoter-
luciferase construct together with C/EBPc plasmid or control
vector in the presence or absence of IL-1b. As shown in Fig. 2E,
IL-1b stimulation induced IL-6 promoter-driven luciferase
expression by over 2.3-fold. However, C/EBPc over-expression
led to an over 50% reduction in the luciferase expression (Fig. 2E).
C/EBPc suppresses IL-1b-induced IL-6 expression in
primary alveolar type II epithelial cells
To further confirm the inhibitory role of C/EBPc in IL-6
expression observed in the MLE12 cells, we isolated primary
alveolar type II epithelial cells from mouse lung. As shown in
Fig. 3A and B, expression of the surfactant protein C was
confirmed using fluorescent staining with a pro-SP-C monoclonal
antibody. The successful isolation of primary alveolar type II
epithelial cells was verified using TEM assay that shows the
lamellar bodies of characteristic features (Fig. 3 C and D). Primary
alveolar type II epithelial cells were infected with Adeno-GFP and
Adeno-C/EBPc, respectively. Our preliminary study shows that
adenoviral transfection efficiency is about 40% (data not shown).
Consistent with the results obtained from MLE12 cells, we found
that over-expression of C/EBPc significantly inhibited IL-6
secretion after IL-1b stimulation (Fig. 3F). Taken together, these
results support the inhibitory role of C/EBPc on IL-1b-induced
IL-6 production in alveolar type II epithelial cells.
IL-1b induces the activation of both C/EBPb/c and NF-kB
in MLE12 cells
Previous studies including ours show that C/EBPb and NF-kB
synergistically activate the IL-6 expression in various immune
cells. Thus, we examined the activation of C/EBPs and NF-kBi n
IL-1b-treated MLE12 cells. As shown in Fig. 4A, IL-1b induces
strong NF-kB DNA-binding activity (mainly p65) in MLE12 cells.
Furthermore, IL-1b treatment also led to the induction of C/EBP
DNA-binding activity in the MLE12 cells (Fig. 4B). The C/EBPb
gene can produce several N-terminally truncated isoforms
including Liver-enriched activator protein (LAP) and liver-
enriched inhibitory protein (LIP) [15]. LAP is a transcriptional
activator in many systems, whereas the function of LIP is
controversial. Using supershift assay, we found that C/EBP
DNA binding species contained both C/EBPb and C/EBPc,i n
IL-1b-treated and untreated cells (Fig. 4B). Moreover, IL-1b
induced the DNA-binding activity of C/EBPc (mainly in the forms
of C/EBPc:c homodimers and C/EBPc:LAP/LIP heterodimers).
C/EBPb and p65 are indispensable for IL-6 expression in
MLE12 cells
To determine if interaction of both NF-kB and C/EBPb with the
IL-6 promoter region was required for the IL-1b-induced IL-6
expression in MLE12 cells, we transfected MLE12 cells with an IL-6
promoter-luciferaseconstructoranL-6promoter-luciferaseconstruct
harboring a mutant in either the NF-kB binding site or the C/EBP
binding site. As shown in Fig. 5A, a mutation in either the NF-kB
binding site or the C/EBP binding site led to a significant decrease of
IL-6 promoter-luciferase activity following IL-1b stimulation com-
pared with non-mutated IL-6 promoter-luciferase. We further
determined the ability of NF-kB and C/EBPb to synergistically
induce the IL-6 promoter-luciferase activity in MLE12 cells. As
shown in Fig. 5B, transient transfection with p65 or C/EBPb
expression vector caused an over 2-fold increase of luciferase activity
when compared with the control vector. Concurrent forced
expression of p65 and C/EBPb led to a 3-fold increase of promoter
activity compared with p65 or C/EBPb alone (Fig. 5B). We next
examined if the synergistic effect was due to the increased p65 DNA
bindingactivity induced byC/EBPbexpression.AsshowninFig.5C,
C/EBPb expression could marginally affect IL-1b-stimulated NF-kB
DNA binding activity. Therefore, interaction between p65 and C/
EBPb might be involved in their synergistic activation of IL-6
promoter activity induced by IL-1b.
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6 production, we transfected MLE12 cells with control siRNA or
siRNA specific for C/EBPb. As shown in Fig. 6A, C/EBPb siRNA
almost completely abrogated C/EBPb expression compared with
control siRNA in MLE12 cells. Furthermore, knockdown of C/
EBPb expression significantly decreased IL-1b-induced IL-6
expression at both mRNA and protein levels (Fig. 6B and C).
We further examined the role of C/EBb in IL-1b-induced IL-6
expression in transfection study using IL-6 promoter-luciferase
assay. Consistent with the results from RT-PCR and ELISAs
(Fig. 6B and C), IL-1b stimulation alone (without transfection of a
C/EBPb expression vector) induced a 2.5-fold increase of
Figure 1. Knockdown of C/EBPc enhances IL-6 production in MLE12 cells. MLE12 cells were treated with 20 ng/ml IL-1b for different time
periods. A, the nuclear proteins were harvested. Activation of C/EBPs was detected by EMSA. B, total cellular RNA was extracted for Real time-PCR
with primers for C/EBPc and GAPDH, respectively. C, the cells were transiently transfected with control siRNA, and C/EBPc-specific siRNA, respectively.
24 h after transfection, RNAs were isolated and RT-PCR was performed by using primers for C/EBPc, and GAPDH, respectively. D and E, MLE12 cells
were transiently transfected with control siRNA or C/EBPc-specific siRNA. 24 h later, cells were stimulated by 20 ng/ml IL-1b for indicated time
periods. D, RNAs were harvested for RT-PCR using primers for IL-6, and GAPDH, respectively. E, the supernatants were harvested for ELISA. Data were
means 6 S. E. M., N=8.
doi:10.1371/journal.pone.0035492.g001
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35492Figure 2. Ectopic expression of C/EBPc inhibits IL-1b-mediated IL-6 expression in MLE12 cells. A, MLE12 cells were infected with control
adenovirus (Adeno-GFP) or C/EBPc expressing adenovirus (Adeno-C/EBPc) at 20 MOI. 24 h after infection, total protein were harvested and subjected
to Western blot using antibodies against C/EBPc and GAPDH, respectively. B, MLE12 cells were infected with Adeno-GFP or Adeno-C/EBPc at 20 MOI.
24 h later, the nuclear extracts were subjected for EMSA. NS and a-c represent normal rabbit IgG, and anti-C/EBPc antibody, respectively. Arrows
indicated C/EBP binding species and supershift bands. C and D, MLE12 cells were infected with Adeno-GFP or Adeno-C/EBPc at 20 MOI. 24 h later, the
cells were stimulated with or without 20 ng/ml IL-1b for indicated time periods. C, RNAs were isolated and RT-PCR was conducted using primers for
IL-6 and GAPDH, respectively. D, the supernatants were harvested for ELISA. Data were expressed as means 6 S. E. M., N=8. E, MLE12 cells were
transfected with indicated plasmids. 24 h later, the cells were treated with or without 20 ng/ml IL-1b. Cell lysates were subjeceted for luciferase
activity measurement. Luminometer values were normalized for expression from a co-transfected thymidine kinase reporter gene. The data were
expressed as means of three experiments 6 S. E. M. ** and *** indicated statistically significant difference-p,0.01 and p,0.001, respectively.
doi:10.1371/journal.pone.0035492.g002
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Moreover, IL-1b treatment of C/EBPb transfectants led to a
25% increase of luciferase activity than the IL-1b stimulation
alone (p,0.001).
C/EBPc suppresses IL-1b-induced IL-6 expression by
inhibiting C/EBPb activity but not NF-kB activity
We reason that C/EBPc suppresses the IL-6 expression through
inhibiting stimulatory C/EBP acitivity. MLE 12 cells were
transfected with 26C/EBP-Luc, a C/EBP-dependent promoter-
reporter containing two copies of a C/EBP binding site, together
with C/EBPc expressing plasmid or control plasmid. As shown in
Fig. 7A, IL-1b stimulation led to a significant increase of 26C/
EBP-Luc expression, and over-expression of C/EBPc resulted in a
reduction of luciferase activity to the basal level. In sharp contrast,
although there is a more than 2-fold IL-1b induction of kB-
Luciferase expression, this activity was not affected by C/EBPc
expression (Fig. 7B). We further show that C/EBPc over-
expression caused a significant decrease of the 26C/EBP-Luc
expression induced by C/EBPb over-expression (Fig. 7C). To
determine if decreased C/EBPb binding by C/EBPc could lead to
the reduced IL-6 expression, MLE 12 cells were transfected with
C/EBPb plasmid in the presence or absence of C/EBPc plasmid.
As shown in Fig. 7D, C/EBPb itself caused a 1.7-fold increase of
IL-6-Luc expression (P,0.01), while over-expression of C/EBPc
led to a significant decrease of the luciferase expression. Together,
these data suggest that C/EBPc inhibits IL-1b-induced IL-6
expression by suppressing C/EBPb activity.
Discussion
Previous study shows that C/EBPc dramatically augments the
activity of C/EBPb in LPS induction of the IL-6 and IL-8
promoters in a B lymphoblast cell line [16]. In another study,
Kaisho et al show that the ability of C/EBPc (-/-) chimera
splenocytes to produce interferon c in response to IL-12 and/or
IL-18 was markedly impaired [13]. To our knowledge, these are
the only two reports indicating a possible role of C/EBPc in
Figure 3. Over-expression of C/EBPc suppresses IL-1b-induced IL-6 production in primary cultured alveolar type II epithelial cells.
A–D, alveolar type II epithelial cells were isolated from C57BL6 mouse, and identified by pro-SP-C immunostaining (A, B), as well as lamellar body
transmission electron microscopy. A, B, and C indicate DIC, fluorescence, and transmission electron microscopy, respectively; and D indicates
enlarged lamellar body. Arrows in A and B indicate staining for pro-SP-C and in C indicate lamellar body. E, alveolar type II epithelial cells were
infected with Adeno-GFP or Adeno-C/EBPc at a MOI of 50. 24 h after infection, the total protein were harvested and subjected for Western blot by
using antibodies against C/EBPc and GAPDH, respectively. F, alveolar type II epithelial cells were infected with Adeno-GFP or Adeno-C/EBPc at a MOI
of 50. 24 h later, the cells were cultured with or without 50 ng/ml IL-1b for another 24 h. The supernatants were subjected for ELISA. Data were
expressed as means 6 S. E. M., N=10.
doi:10.1371/journal.pone.0035492.g003
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35492regulating the expression of inflammatory mediators. In this study,
we show that C/EBPc expression is induced by IL-1b in alveolar
type II epithelial cells. We further show that C/EBPc is a critical
regulator of IL-1b-mediated IL-6 production.
Although alveolar type II epithelial cells only cover about 5% of
the alveolar surface area, there is increasing evidence that they
play a significant role in lung inflammatory diseases. IL-1b is a
critical inducer of immune and inflammatory responses by
mediating activation of alveolar type II epithelial cells, leading to
pro-inflammatory cytokine production such as IL-6 [17]. IL-6,
which is a pleiotropic cytokine produced by a variety of cell
populations such as alveolar macrophages and alveolar type II
cells, plays an important role in both acute and chronic lung injury
[18,19]. IL-6 expression is mainly regulated at transcriptional
Figure 4. C/EBPb and NF-kB are activated by IL-1b treatment in MLE12 cells. MLE12 cells were stimulated with 20 ng/ml IL-1b for 3 h. The
nuclear proteins were harvested. Activation of NF-kB (A) and C/EBP (B) were detected by EMSA. N, a, b, d, e, and c represent normal rabbit IgG, anti-C/
EBPa antibody, anti-C/EBPb antibody, anti-C/EBPd antibody, anti-C/EBPe antibody, and anti-C/EBPc antibody, respectively. Arrows indicated C/EBPs,
NF-kB binding species and supershift bands.
doi:10.1371/journal.pone.0035492.g004
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binding to the cis-acting elements of the IL-6 promoter region,
such as NF-kB and C/EBPb/d. For example, C/EBPb and -d
have both been shown to activate a reporter gene controlled by the
IL-6 promoter in transient expression assays [8,20]. Furthermore,
the stable expression of C/EBPb in a murine B lymphoblast cell
line is sufficient to confer LPS inducibility of IL-6 expression [21].
Importantly, NF-kB and C/EBPb synergistically activate the IL-6
promoter, and consistent with this, direct interaction between the
C/EBPb bZIP and the NF-kB Rel homology domain has been
observed [22], as well as cooperative binding of the two factors
[22]. In addition, the NF-kB site of the IL-6 promoter is required
for the activity of the C/EBPb bZIP in the absence of amino-
terminal motifs [23]. All of these studies suggested a mechanism
for IL-6 activation whose essential feature is the requirement for
the bZIP region of C/EPBb to synergize with NF-kB, although
this remains to be further investigated. In addition, it has been
recently shown that IL-1b-induced IL-6 production in alveolar
type II cells is associated with the activation of both IL-1 receptor-
associated kinase-4 and phosphatidylinositol 3-kinase [24]. How-
ever, in alveolar type II cells, molecular mechanisms involved in
IL-1b-induced IL-6 production remains largely unknown. In the
current study, we find that the binding activity of both NF-kB and
C/EBPb to their regulatory elements in the IL-6 promoter is
significantly elevated by IL-1b stimulation in alveolar epithelial
cells. Our data further indicate that both C/EBPb and p65 are
indispensable for IL-1b-induced IL-6 expression, which is
consistent with the observation in other cell types.
Our finding that C/EBPc can regulate IL-1b-induced IL-6
production in alveolar type II epithelial cells is interesting. C/
EBPc has been considered as an inhibitor of other C/EBP family
members. For example, C/EBPc inhibits C/EBPb-mediated
HIV-1 long terminal repeat-driven transcription in human brain
cells [25]. In addition, C/EBPc represses C/EBPb-mediated
induction of alcohol dehydrogenase expression in the rat livers
[16]. These results are consistent with the fact that C/EBPc lacks
known activation domains and is essentially a C/EBP bZIP
domain [12]. In contrast, C/EBPc can also act as a transcription
activator. For example, C/EBPc has been shown to be a positive
regulator of IFN-c expression in splenocytes and NK cells [13],
and gamma-globin expression in fetal liver [26]. Furthermore,
previous studies demonstrated that augmentation of C/EBPb
activity on the IL-6 and IL-8 promoters by C/EBPc required
formation of a heterodimeric leucine zipper and co-expression of
NF-kB [16]. Interestingly, C/EBPc inhibits C/EBPb- and C/
EBPd-mediated transactivation of a reporter gene in fibroblasts in
a leucine zipper-dependent manner, but it has no suppressive
function in HepG2 hepatoma cells [27]. These findings together
indicate that C/EBPc has complex effects on gene transcription.
Our current finding that C/EBPc suppresses IL-1b-induced IL-6
production in alveolar type II epithelial cells further suggests that
its function may be cell specific.
The exact molecular mechanism whereby C/EBPc regulates
gene expression is not clear. In IL-1b-stimulated alveolar epithelial
cells, C/EBPc exists as both homodimers (C/EBPc:c) and
heterodimers (C/EBPc:b) (Fig. 4B). It is possible that the lack of
one transactivation domain in C/EBPc:b heterodimers may
contribute to the inhibitory effect of C/EBPc. On the other
hand, in C/EBPc-overexpressed cells, the major C/EBPc binding
species is C/EBPc:c homodimers (Fig. 2B), suggesting that C/
EBPc:c homodimers may compete with the stimulatory C/EBP
b:b (LAP:LAP or LAP:LIP) to bind to IL-6 promoter region. In
addition, we observed an increased C/EBPc:b heterodimers
(LAP:c) binding to IL-6 promoter in C/EBPc-overexpressed cells
Figure 5. C/EBPb and NF-kB p65 are involved in IL-1b-induced
IL-6 expression. A, B and C. MLE12 cells were transfected with
indicated plasmids. 24 h later, the cells were treated with or without
20 ng/ml IL-1b. The cell lysates were subjected for luciferase activity
measurement. Luminometer values were normalized for expression
from a co-transfected thymidine kinase reporter gene. The data were
expressed as means of three experiments 6 S. E. M. ** and *** indicated
statistically significant difference-p,0.01, and p,0.001, respectively.
doi:10.1371/journal.pone.0035492.g005
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35492Figure 6. Knockdown of C/EBPb by siRNA inhibits IL-1b-induced IL-6 production in MLE12 Cells. A, MLE12 cells were transfected with
40 nM control siRNA or C/EBPb-specific siRNA. 24 h later, RNAs were isolated and RT-PCR was performed by using primers for C/EBPb and GAPDH,
respectively. B and C, MLE12 cells were transfected with 40 nM control siRNA or C/EBPb si RNA. 24 h later, the cells were incubated with or without
20 ng/ml IL-1b for different time periods. B, RNAs were isolated and RT-PCR was performed by using primers for IL-6 and GAPDH, respectively. C,
Supernatants were harvested for ELISA. The data were expressed as means6 S. E. M., N=8. D, MLE12 cells were transfected with indicated plasmids.
24 h later, the cells were treated with 20 ng/ml IL-1b for 6 h. Cell lysates were subjected for luciferase activity measurement. Luminometer values
were normalized for expression from a co-transfected thymidine kinase reporter gene. The data were expressed as means of three experiments 6 S.
E. M.
doi:10.1371/journal.pone.0035492.g006
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EBPb pool in the nucleus. However, whether C/EBPc is a
preferential dimerization partner for C/EBPb or C/EBPc:b
heterodimers have a higher affinity than C/EBPb:b in lung
epithelial cells remains an open question. Interestingly, C/EBPc
does not seem to affect NF-kB DNA binding (Fig. 7B and data not
shown), suggesting that C/EBPc has no effect on the synergistic
activity between NF-kB and C/EBPb in IL-6 promoter in alveolar
epithelial cells (Fig. 5B).
Taken together, we identified a previously unrecognized role for
C/EBPc in inflammation in alveolar epithelial cells. Not
surprisingly, many transcription factors such as NF-kB and C/
EBPb are activated in the acute lung inflammatory reaction.
However, our current study suggests that the acute inflammatory
response in the lung can also be counter-regulated by other
transcription factors such as C/EBPc (Figure 8). Understanding
the underlying roles and mechanisms whereby C/EBPc regulates
the network of inflammatory system in the lung may be a crucial
step for the development of new therapeutic targets for treatment
of lung inflammatory diseases.
Materials and Methods
Cells and Reagents
Murine lung epithelial cells (MLE12) and HEK293 cells were
obtained from American Type Culture Collection (CRL-2110
TM,
Manassas, VA), and cultured in DMEM/F-12 (Fisher Scientific,
Pittsburgh, PA) supplemented with 5% fetal calf serum (FCS,
Figure 7. C/EBPc suppresses IL-1b-induced IL-6 expression by inhibiting C/EBPb, not NF-kB activation in MLE 12 cells. A–D, MLE12
cells were transfected with indicated plasmids. 24 h later, cells were treated with or without 20 ng/ml IL-1b. The cell lysates were subjected for
luciferase activity measurement. Luminometer values were normalized for expression from a co-transfected thymidine kinase reporter gene. The data
were expressed as means of three experiments 6 S. E. M. ** and *** indicated statistically significant difference-p,0.01 and p,0.001, respectively.
doi:10.1371/journal.pone.0035492.g007
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incubator at 37uC with 5% CO2. Recombinant mouse IL-1b (401-
ML) was purchased from R&D Systems, Minneapolis, MN.
Expression Vectors and Promoter Reporters
Full-length mouse C/EBPc cDNA was amplified from total
RNA of the mouse lung using reverse transcription-PCR
(Invitrogen, Carlsbad, CA), sequenced, and inserted into
pcDNA3.1(+) (Invitrogen, Carlsbad, CA). Recombinant adenovi-
rus containing mouse C/EBPc (Adeno-C/EBPc) was constructed
by using BD Adeno-X
TM Expression System 1 (BD Biosciences,
Palo Alto, CA). To generate the virus, Adeno-C/EBPc was
digested with PacI and transfected to HEK-293 cells according to
the manufacturer’s instructions. Recombinant adenoviruses were
purified by BD Adeno-X virus purification kit (BD Biosciences,
Palo Alto, CA), and stored in aliquots at 280uC. The viral stocks
were tittered using Adeno-X Rapid Titer Kit (D Biosciences, Palo
Alto, CA). The mouse IL-6 promoter-reporter (2250 to +1), IL-6
promoter-reporter containing a mutated NF-kB binding site, as
well as the C/EBPb and NF-kB p65 expression plasmids were
kindly provided by Richard C. Schwartz (Michigan State
University). Mouse IL-6 promoter-reporter containing a mutated
C/EBP binding site (2161 to 2147) was kindly provided by Gail
A. Bishop (University of Iowa). NF-kB promoter reporter was
obtained from Promega. C/EBP promoter reporter, 26C/EBP-
Luc containing two copies of a C/EBP binding site, was kindly
provided by Peter F. Johnson (NCI-Frederick).
Adenovirus Transfection
Cells were grown to 90% confluence, infected with Adeno-GFP
and Adeno-C/EBPc, respectively, at 20 MOI. 24 h later, proteins
were harvested for the analysis of C/EBPc expression. In some
experiments, the cells were treated with 20 ng/ml IL-1b for the
indicated time. The supernatants were collected for ELISA
analysis.
Luciferase Assay
Transient transfections were performed with 8610
4 cells plated
in 12-well plates by using 0.5 mg of total DNA and 1.5 mlo f
FugeneH6 Transfection Reagent (Roche, Indianapolis, IN) in 50 ml
of Opti-MEM I medium (Invitrogen, Carlsbad, CA). 24 h after
transfection, the cells were either incubated with or without
20 ng/ml IL-1b for indicated time. Cell lysates were subjected to
luciferase activity analysis by using the Dual-Luciferase Reporter
Assay System (Promega, Madison, WI).
siRNA Transfection
Transient siRNA transfections were performed in 6-well plates
by transfecting MLE 12 cells with control siRNA or C/EBPb/c
siRNA (40 nM) (Santa Cruz, CA) using 5 ml Lipofectamine
TM
2000 in 500 ml of Opti-MEM I medium (Invitrogen, Carlsbad,
CA). 12 h after siRNA transfection, the cells were treated with or
without 20 ng/ml IL-1b for different time points. Supernatants
were collected for ELISA.
ELISA
Both MLE12 cells and primary cultured alveolar type II
epithelial cells were stimulated by IL-1b for the indicated time.
The supernatants were centrifuged at 3000 rpm for 5 min, and the
cell-free supernatants were harvested for IL-6 measurements by
using a commercially available ELISA kit (R&D Systems,
Minneapolis, MN) according to the manufacturer’s protocol.
RNA Isolation and Detection of mRNA by Quantitative
Real-Time PCR (qPCR)
Total RNAs were extracted from cells with Trizol (Invitrogen,
Carlsbad, CA) according to the manufacturer’s procedure. After
isolation, total cellular RNA was incubated with RQ1 RNase-free
DNase (Promega, Madison, WI) to remove contaminating DNA.
2 mg of total RNA was submitted to reverse transcription by using
the Superscript II RNase H
2 Reverse Transcriptase (Invitrogen,
Carlsbad, CA). The levels of mRNA of C/EBPc and GAPDH
were determined by qPCR. PCR was performed with primers for
C/EBPc:5 9 primer, 59-GCA AGC AAA GCA AAA AGA GC-39
and 39 primer, 59-GCT TCC AAC CGT TCA TTC TC-39;
GAPDH: 59 primer, 59-GCC TCG TCT CAT AGA CAA GAT
G-39 and 39 primer, 59-CAG TAG ACT CCA CGA CAT AC-39.
Following reverse transcription, the cDNA (2 ml) was amplified
and quantified using a Sequence Detection System (SDS 7300,
Applied Biosystems, Foster City, CA) and a PCR universal
protocol as follows: AmpliTaq Gold activation at 95uC for 15 s
and, annealing/extension at 60uC for 1 min. The fluorescence of
the double-stranded products accumulated was monitored in real
time. The relative mRNA levels were normalized to levels of
GAPDH mRNA in the same sample. The expression of IL-6 by
RT-PCR was determined as previously described [28].
Western Blot Analysis
Both MLE12 and primary cultured AEC II were lysed in cold
RIPA buffer. Samples containing 80 mg protein were electropho-
resed in a 12% polyacrylamide gel and transferred to a PVDF
membrane. Membranes were incubated with rabbit anti-C/EBPc
antibody (provided by Peter F. Johnson) and rabbit anti-GAPDH
antibody (Cell Signaling, Danvers, MA), respectively. After 3
washes in TBST, the membranes were incubated with a 1:5,000
dilution of horseradish peroxidase-conjugated donkey anti-rabbit
Figure 8. Diagram delineates a role for C/EBPc in the AECII
inflammatory responses. Inflammatory stimuli in the lung such as IL-
1b trigger activation of AECII. AECII activation is characterized by
increased nuclear translocation, DNA binding of transcription factors
such as NF-kB and C/EBPb, and subsequent production of the pro-
inflammatory mediators such as IL-6. This inflammatory response is
endogenously regulated by the dominant-negative members of the
same family of transcription factors such as C/EBPc by forming
homodimmers themselves and heterodimmers with C/EBPb to compete
with C/EBPb:b dimmers to bind to promoter regions.
doi:10.1371/journal.pone.0035492.g008
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developed by enhanced chemiluminescence technique according
to the manufacturer’s protocol (Thermo Fisher Scientific, Rock-
ford, IL).
Isolation of Alveolar Type II Epithelial Cells
Alveolar type II epithelial cells from C57BL6 mice were isolated
and cultured using a method described previously [29]. In all
experiments, specific pathogen-free male C57BL/6 mice obtained
from Jackson Laboratory (Bar Harbor, ME) were used. All
procedures involving mice were approved by the Animal Care and
Use Committee of Harvard Medical School. Using biotinylated
CD32 and CD45 mAbs, lymphocytes were removed from alveolar
type II epithelial cells by streptavidin-magnesphere. The methods
achieved high yields (5–7 millions/mouse), high purity (92–95%)
and viability (.95%). Alveolar type II epithelial cells were
identified by following methods: a) alkaline phosphatase staining
[30], b) lamellar body identified by tannic acid staining and by
transmission electron microscopy [31], c) immunochemistry for
alveolar type II epithelial cells using monoclonal anti-pro-SP-C
[31]. Cells were also identified by pan-cytokeratin antibodies
(Sigma-Aldrich, St. Louis, MO) [4]. We also used an improved
method to maintain the primary cell culture with some
modifications [32,33].
Transmission Electron Microscopy (TEM)
TEM was used to characterize freshly isolated alveolar epithelial
type II cells using modified Karnovsky’s fixative [34]. Images were
taken and analyzed according to our previous published methods
[35,36,37].
Immunostaining
For immunocytochemistry, the cells were fixed in 3.7%
paraformaldehyde and non-specific binding was blocked with
blocking buffer for 30 minutes [38]. Cells were incubated with
primary antibodies at 1/300 dilution in blocking buffer for 1 h and
washed three times with wash buffer. After incubation with
appropriate fluorophore-conjugated secondary antibodies, the
coverslips were mounted on slides with Vectashield mounting
medium. The samples were observed on an LSM 510 Meta
confocal microscope (Carl Zeiss MicroImaging), and data were
processed using the software provided by the manufacturer or
Image J software [31].
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts of MLE12 cells were prepared as follows. Cells
were lysed in 15 mM KCl, 10 mM HEPES (pH 7.6), 2 mM
MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, 0.1% (v/v) Nonidet
P-40, 0.5 mM phenylmethylsulfonyl fluoride, and complete
protease inhibitors (Roche, Indianapolis, IN) for 10 min on ice.
Nuclei were pelleted by centrifugation at 14,0006g for 20 sec at
4uC. Proteins were extracted from nuclei by incubation at 4uC
with vigorous vortexing in buffer C (420 mM NaCl, 20 mM
HEPES (pH 7.9), 0.2 mM EDTA, 25% (v/v) glycerol, 1 mM
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, and com-
plete protease inhibitors (Roche, Indianapolis, IN). Protein
concentrations were determined by Bio-Rad protein assay kit
(Thermo Fisher Scientific, Rockford, IL). The EMSA probes were
double-stranded oligonucleotides containing a murine IL-6 C/
EBP binding site (59-CTAAACGACGTCACATTGTG-
CAATCTTAATAAGGTT-39annealed with 59-TGGAAACCT-
TATTAAGATTGCACAATGTGACGTCGT-39, kindly provid-
ed by Richard Schwartz, Michigan State University), or a NF-kB
consensus oligonucleotide (AGTTGAGGGGACTTTCC-
CAGGC, Promega, Madison, WI). C/EBP probes were labeled
with a [
32P] ATP (3,000 Ci/mmol at 10 mCi/ml, GE Healthcare,
Piscataway, NJ). NF-kB probes were labeled with c [
32P] ATP
(3,000 Ci/mmol at 10 mCi/ml, GE Healthcare, Piscataway, NJ).
DNA binding reactions were performed at room temperature in a
25 ml reaction mixture containing 6 ml of nuclear extract (1 mg/ml
in buffer C) and 5 mlo f5 6 binding buffer (20% (w/v) Ficoll,
50 mM HEPES pH 7.9, 5 mM EDTA, 5 mM dithiothreitol). The
remainder of the reaction mixture contained KCl at a final
concentration of 50 mM, Nonidet P-40 at a final concentration of
0.1%, 1 mg of poly (dI-dC), 200 pg of probe, bromphenol blue at a
final concentration of 0.06% (w/v), and water to final volume of
25 ml. Samples were electrophoresed through 5.5% polyacryl-
amide gels in 16 TBE at 190 V for approximately 3.5 h, dried
under vacuum, and exposed to X-ray film. For supershifts, nuclear
extracts were preincubated with antibodies (1 to 2 mg) for 0.5 h at
4uC prior to the binding reaction. The following antibodies were
purchased from Santa Cruz, CA: NF-kB p50, p52, p65, RelB, c-
Rel, C/EBPa, C/EBPb, C/EBPd, C/EBPe, C/EBPc, and
normal rabbit immunoglobulin G.
Statistical Analysis
All values were expressed as the mean 6 S. E. M. Significance
was assigned where p,0.05. Data sets were analyzed using
Student’s t test or one-way ANOVA, with individual group means
being compared with the Student-Newman-Keuls multiple
comparison test.
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